<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568460</url>
  </required_header>
  <id_info>
    <org_study_id>2019P002671</org_study_id>
    <nct_id>NCT04568460</nct_id>
  </id_info>
  <brief_title>Standing Tall (Yima Nkqo)</brief_title>
  <official_title>Standing Tall (Yima Nkqo): A Pilot Randomized Controlled Trial of a Community-Based Intervention to Improve Health Outcomes for Young Adults Newly Diagnosed With HIV in South Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Desmond Tutu HIV Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose the Standing Tall study, a prospective randomised study of strategy&#xD;
      to optimize community-based ART initiation in South Africa. Investigators will work closely&#xD;
      with community members to integrate community-based ART. One hundred participants will be&#xD;
      enrolled and followed for a total of up to 6 months. Those in the intervention arm will be&#xD;
      provided with the ST intervention which includes a behavioral component and access to ART.&#xD;
      The intervention will be linked to a clinic through a &quot;Nurse Initiated Management of ART.&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The premise for our study is based on three decades of HIV research that supports the need&#xD;
      for multi-component, multisystem interventions to promote testing, and adherence to treatment&#xD;
      and care for young people living with HIV. The proposed intervention, Standing Tall, is&#xD;
      informed and guided by Social Action Theory - a conceptual framework reflecting a holistic&#xD;
      understanding of health behavior and motivational factors that foster and maintain behavior&#xD;
      change. Standing Tall, a pilot randomized controlled trial, is designed to address&#xD;
      multi-factorial barriers using (1) a socio-behavioral group intervention; (2) social support;&#xD;
      (3) provision of immediate ART and refills. The primary outcome is ART initiation at three&#xD;
      months, and the secondary outcome is viral load suppression at six months. Other&#xD;
      tertiary/exploratory outcomes include behavioral outcomes and process evaluation of the&#xD;
      intervention itself, and the use of point-of-care diagnostics.&#xD;
&#xD;
      The administrative supplemental funding provides support for an additional objective of this&#xD;
      study: to understand how best to use point-of-care (POC) testing in clinical practice in&#xD;
      order to improve HIV care and treatment for South African young people. Understanding patient&#xD;
      perspectives and perceived barriers is critical to developing feasible, acceptable, and&#xD;
      effective protocols for implementing POC testing. The primary aim for achieving this&#xD;
      objective is to assess patient perspectives regarding POC testing through in-depth,&#xD;
      semi-structured interviews among study participants enrolled in Standing Tall's second aim.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ART Initiation</measure>
    <time_frame>Three Months</time_frame>
    <description>ART initiation will be assessed via a self-report measure of participants who will report whether they have or have not initiated ART.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ART Initiation</measure>
    <time_frame>Three Months</time_frame>
    <description>ART initiation will also be assessed via a point-of-care diagnostic detecting Tenofovir concentrations in participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Load Suppression</measure>
    <time_frame>Six Months</time_frame>
    <description>Viral suppression will be measured from plasma specimen collected at 6 months from enrollment. Persons missing plasma HIV RNA results for any reason (e.g. death) will be counted as not initiated. Additional records obtained through PHDC and NHLS will provide additional data (such as plasma HIV RNA concentration) that will be used for confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Household Food Security</measure>
    <time_frame>Six Months</time_frame>
    <description>We will assess household food security via a self-report questionnaire. Participants will report how many times in the last 30 days they experienced anxiety and uncertainty about household food access and insufficient quality and quantity on a scale from rarely to more than 10 times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Health</measure>
    <time_frame>Six Months</time_frame>
    <description>We will assess generalized anxiety disorder using the GAD-7 questionnaire and major depressive disorder using the Patient Health Questionnaire (PHQ-9). Participants will self-report how many times in the last 2 weeks they experienced symptoms from not at all to nearly every day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substance Use</measure>
    <time_frame>Six Months</time_frame>
    <description>We will assess participants alcohol and drug use via the SAMISS (Substance Use Subsection - AUDIT) questionnaire. Participants will self-report how many times a month they partake in alcohol or drug use on a scale ranging from never to less than monthly, to daily. Participants may also refuse to answer questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellness</measure>
    <time_frame>Six Months</time_frame>
    <description>We will assess participant's comprehensive health status measure using the Measure of Wellness (Medical Outcomes Study-HIV) survey. Participants will self-report how frequently they experienced symptoms relating to mental health, quality of life, health distress, cognitive function, energy/fatigue, overall health, role function, physical function, pain, and social function on a scale from all of the time to none of the time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress</measure>
    <time_frame>Six Months</time_frame>
    <description>We will assess participant's ability to cope with stressful live events using the brief COPE self-report questionnaire. Participants will indicate how frequently they have utilized different coping mechanisms on a scale from not at all to a lot.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resilience</measure>
    <time_frame>Six Months</time_frame>
    <description>We will assess participant's resilience using the Connor-Davidson Resilience Scale (CDRISC-100) self-report questionnaire. Participants will indicate the extent to which they identify with resilience statements from a scale from not at all true to true nearly all the time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implementation Factors</measure>
    <time_frame>Six Months</time_frame>
    <description>Acceptability, feasibility and appropriateness of our intervention will be quantitatively be measured as participants indicate how confident they feel in varying aspects of the intervention from not at all confident to completely confident.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Acceptability</measure>
    <time_frame>Six Months</time_frame>
    <description>Participant's views of the acceptability of our intervention will be measured using qualitative exit interviews.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Fidelity</measure>
    <time_frame>Six Months</time_frame>
    <description>The fidelity of our intervention will be measured using a fidelity monitoring tool. A research assistant (RA) will report yes, no, partially, or not applicable in response to statements about facilitators. The RA will also assess how well the facilitator did using a scale from poor to always.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Intervention Group Sessions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group sessions will be delivered by lay health counselors. The sessions will reflect principles of co-learning, participatory design, and empowerment to promote engagement of young people in critical thinking and problem solving - including modeling, roleplaying, and interactive activities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This is the standard of care arm. Participants newly diagnosed with HIV will get a referral to the local primary health care setting of their choice for further management, including ART.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intervention Group Sessions</intervention_name>
    <description>Participants will undergo a multi-session group intervention over the course of six months.</description>
    <arm_group_label>Intervention Group Sessions</arm_group_label>
    <other_name>Yima Nkqo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Complete an assessment of understanding&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Are between ages 18-24&#xD;
&#xD;
          -  Present to Tutu Tester vans and test HIV+&#xD;
&#xD;
          -  Are ART-na√Øve&#xD;
&#xD;
          -  Are English or isiXhosa speakers&#xD;
&#xD;
          -  Reside in the Cape Town metro area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant (must be referred to antenatal clinic if living with HIV)&#xD;
&#xD;
          -  Test positive for tuberculosis (must be referred to clinic for TB treatment prior to&#xD;
             ART initiation)&#xD;
&#xD;
          -  Are unable to understand the process of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ingrid T Katz, MD, MHS</last_name>
    <phone>617.525.8194</phone>
    <email>ikatz2@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda-Gail Bekker, MBChB, PhD</last_name>
      <phone>+27 (0) 21 406 6966</phone>
      <email>Linda-Gail.Bekker@hiv-research.org.za</email>
    </contact>
    <investigator>
      <last_name>Linda-Gail Bekker, MBChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Ingrid Theresa Katz, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

